AngioDynamics (ANGO) Tops Q4 EPS by 3c; Guides FY17

AngioDynamics (NASDAQ: ANGO) reported Q4 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $93.4 million versus the consensus estimate of $88.41 million.

GUIDANCE:

AngioDynamics sees FY2017 EPS of $0.62-$0.65, versus the consensus of $0.66. AngioDynamics sees FY2017 revenue of $355-360 million, versus the consensus of $358.6 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance